Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565080 | 0.86 | GPR119 (0.39) | DPP4GPR119HPGDNPC1ALDH1A1 | |
| SCHEMBL2940070 | 0.84 | DPP4 (0.40) | DPP4GPR119HPGDNPC1ALDH1A1 | |
| SCHEMBL13316251 | 0.73 | HPGD (0.46) | DPP4GPR119HPGDNPC1ALDH1A1 | |
| SCHEMBL1059934 | 0.72 | GPR119 (0.41) | DPP4GPR119HPGDNPC1ALDH1A1 | |
| SCHEMBL1059936 | 0.72 | GPR119 (0.41) | DPP4GPR119HPGDNPC1ALDH1A1 | |
| SCHEMBL1059411 | 0.72 | GPR119 (0.41) | DPP4GPR119HPGDNPC1ALDH1A1 | |
| SCHEMBL1059933 | 0.72 | GPR119 (0.41) | DPP4GPR119HPGDNPC1ALDH1A1 | |
| SCHEMBL4546601 | 0.71 | HPGD (0.55) | DPP4GPR119HPGDNPC1ALDH1A1 | |
| SCHEMBL6974258 | 0.71 | HPGD (0.55) | DPP4GPR119HPGDNPC1ALDH1A1 | |
| SCHEMBL13600068 | 0.70 | GPR119 (0.56) | DPP4GPR119HPGDNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773338-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7618987-B2 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK & CO., INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618987-B2 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK & CO., INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618987-B2 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK & CO., INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK SHARP & DOHME CORP. | 2007-08-16 | — | — | US | disclosed |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK SHARP & DOHME CORP. | 2007-08-16 | — | — | US | disclosed |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK SHARP & DOHME CORP. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MC4R, MC5R, MC3R | DPP4 138/4885GPR119 12/4885HPGD 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.